Mass Tort brief
Secret Settlements and New Liability Frontiers
Tech giants buy silence on youth addiction while federal courts reshape medical device, pharma, and toxic tort liability.
Mass Tort
Mass Tort
Tightened federal expert witness rules gutted the baby food toxic tort docket — closing off multi-billion-dollar claims before they could reach a jury.
BackgroundA 2021 US Congressional inquiry uncovered trace amounts of lead, arsenic, and cadmium across commercial infant foods, sparking national class actions. Parents alleged the metals caused autism and ADHD, but defendants countered that trace mineral levels occur naturally in soil.
- The court ruled that plaintiffs' epidemiological experts lacked reliable peer-reviewed methodology to prove ambient heavy metal ingestion causes childhood neurodevelopmental disorders.
- Corporate defense lawyers are using newly tightened federal Rule 702 reliability standards to knock out toxic tort dockets before expensive discovery begins.
- Israeli commercial distributors importing international baby food brands avoid secondary product liability under Health Ministry consumer safety regulations, calming domestic retailers.
Mass Tort
Device makers let sales reps tweak spinal implants to hit revenue targets — exposing manufacturers to sweeping liability that threatens hospital sales models.
BackgroundSpinal cord stimulators are surgically implanted pulse generators that deliver electrical currents into the spine to block chronic pain signals. Israeli medical centers implant hundreds of units each year, relying on manufacturer representatives for technical calibration during recovery.
- Centralized federal proceedings in Illinois focus on battery burns, lead migrations, and unauthorized device reprogrammings conducted outside supervised hospital operating rooms.
- Plaintiffs argue device makers used aggressive sales commissions to incentivize reps to override physician instructions during unmonitored home visits.
- Israel's Health Ministry opened a review of medical device support protocols, evaluating whether local clinical sales reps require formal practitioner licensing.
Mass Tort
Teva produces healthy operating cash, but a decade of US mass-tort settlement installments leaves little room for dividends or defensive errors.
BackgroundTeva negotiated a $4.25B nationwide settlement framework in 2022 to resolve thousands of state and municipal opioid marketing lawsuits. The agreement spread cash payouts across 13 years while obligating the Tel Aviv pharma giant to distribute generic addiction reversal treatments.
- Teva paid substantial settlement tranches to US state attorneys general this quarter, restricting liquidity available for shareholder dividends on the Tel Aviv Stock Exchange.
- Active product liability dockets, including federal Paragard IUD contraceptive claims in Georgia, threaten additional reserve charges alongside Teva's legacy opioid payout commitments.
- Chief Executive Richard Francis stressed that revenue from high-margin biosimilar launches is essential to service annual legal obligations while paring debt.
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
